StemLife Receives Takeover Offer At RM0.45 Per Share
Stem cell banking company StemLife has received a mandatory takeover offer from its major shareholder, Singapore-listed Cordlife Group, to acquire the remaining 67 percent stake it does not own in the company for RM0.45 per share.
The take-over offer was triggered after Cordlife, already a major shareholder of firm, crossed the 33 percent threshold with the purchase of 3 million shares or 1.2 percent of the company on 12 November.
Other notable shareholders in StemLife include Berjaya Corporation (10 percent) and JP Morgan Chase (4.6 percent). The company has said that its board will hold a meeting to deliberate the offer and make an announcement in due course.
Significance: The offer price of RM0.45 represents a RM0.025 or 5.9 percent premium against StemLife’s closing price of RM0.425 on 12 November. It was noted that Cordlife does not intend to maintain the listing status of the firm if the all-cash offer, which is worth RM1.4 billion, goes through.
Do not sell this counter. Cordlife has bigger plans but want it cheap. The regenerative industry is starting to pick up. The assets of this company is substantial,cash and real estate. The business is still profitable. If not Cordlife would not buy.
CordLife has been buying @o.45 in open market to ensure its takeover bid wld be successful. This C9 has good potential to grow exponentially. Look at TMC, the share wld be 50 sen easily if it is still listed.....provided all who have faith in this Co reject the 0.45 offer.
Look at Japan, the govt. is supporting their Regenerative Medicine industry. They are buying biotech companies dealing with stem cells. Even Mesoblast of Australia is going to Japan get their products commercially available. Cordlife is doing well making profits and expanding in Asia. So you think they will lose money in Stemlife?? They want to buy cheap lah. The reg med industry will definitely grow in the near future.
I strongly agreed with drkschua59. The reg med industry is the future, either near term or long term. But, I will make sure the management team is trustworthy & sincere in doing businesses. There are too many conman management in KLSE. Must be very careful.
The present board of directors is definitely more professionally qualified. Except I don't know whether they are more loyal to Cordlife or dedicated to rejunavate Stemlife. The business is ongoing and the staff are working hard. One client of cord tissue banking is worth 3 of cord blood. I hope they cannot gather enough shares to take it private. I want the board to give more back to loyal shareholders. The board have not explained to the sharehokders why it is so important to take it private. Perhaps they want to enrich Cordlife and themselves. They should offer in exchange some cordlife shares.
Basically Stemlife is here to stay for a long time. As i have said Cordlife sees great future but they want it all for themself. Taking it private also mean doing a lot more without having to face both the shareholders and the securities commission. More can be achieved this way and when they want to cash out again, they relist when the situation is much better ie when regenerative medicine industry is booming.
Type Announcement Subject PUBLIC SHAREHOLDINGS SPREAD Description StemLife Berhad ("StemLife" or "The Company") Non-compliance with Public Shareholding Spread pursuant to Rule 8.02(1) of the ACE Market Listing Requirements ("LR") of Bursa Malaysia Securities Berhad ("Bursa Securities") We refer to the announcements dated 22 December 2015, 23 December 2015 and 28 January 2016 and 11 February 2016 (“Earlier Announcements”). Unless otherwise stated, all definitions and terms used in this announcement shall have the same meaning as stated in the Earlier Announcements in relation to the Public Shareholdings Spread.
The Board of Directors wishes to announce that the Company will be applying to Bursa Securities for an extension of time in order to implement the necessary procedures to withdraw its listing status from the Official List of Bursa Securities in accordance with Chapter 16 of the LR.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....